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Abstract 
 
Improvements in surgery have resulted in more women with repaired congenital heart disease 
surviving to adulthood. Women with congenital heart disease, who wish to embark on 
pregnancy require pre-pregnancy counselling. This consultation should cover several issues 
such as the long-term prognosis of the mother, fertility and miscarriage rates, recurrence risk of 
congenital heart disease in the baby, drug therapy during pregnancy, estimated maternal risk 
and outcome, expected fetal outcomes, and plans for pregnancy. Prenatal genetic testing is 
available for those patients with an identified genetic defect using pre-gestational diagnosis or 
prenatal diagnosis chorionic villous sampling or amniocentesis. Centralisation of care may be 
needed for high-risk patients, however, this should be specified and highlighted. Finally, 
currently there are no recommendations addressing the issue of the delivery. It is crucial that a 
dedicated plan for delivery should be available for all cardiac patients. The maternal mortality in 
low-to-middle income countries is 14 times higher than in high-income countries and needs 
additional aspects and dedicated care.  
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Introduction 
The population of adult patients with congenital heart defects continues to increase worldwide 
and, inevitably, as they achieve reproductive maturity, more women are contemplating 
pregnancy. Physicians, including non-specialists, are challenged by the questions of how to 
organize the optimal provision of preconception counselling and subsequent care during 
pregnancy for these patients.  In 2011, the European Society of Cardiology (ESC) produced 
guidelines for pregnancy in cardiovascular disease. (14) These guidelines  focused on the 
medical conditions to define who are at high-risk and should be counselled against pregnancy 
and what treatment should or should not be given. Although this document is extremely 
valuable, the recommendations are primarily written from the perspective of the type of 
anatomical defect and its haemodynamic or electrophysiological implications. As a result, the 
recommendations cannot be used to define who has to be treated where and do not provide in-
depth information on patients with congenital heart defects. Standardized care and research 
evidence are both underdeveloped. In the absence of evidence from randomized-controlled-
trials, there is a clear need to provide practical guidance to clinicians. The most important issue 
in providing preconceptional counselling is early referral, optimally long before pregnancy is 
considered. Patients in whom pregnancy is contraindicated should be clearly counseled and 
effective, safe contraceptive options discussed. In other patients, diagnostic and sometimes 
treatment procedures should be performed pre-pregnancy to minimize their risk of deterioration 
during pregnancy. In addition, although the importance of making and widely disseminating a 
plan for delivery is recognized, there are no recommendations addressing the mode, timing, 
location or necessary resources for delivery. Finally, specific issues for low resource setting 
should be highlighted. To meet this need, the ESC working group on Grown-up Congenital 
Heart Disease, together with the International Federation of Gynecology and Obstetrics, 
appointed a Taskforce to write this position paper; the group including cardiologists, 
obstetricians and anesthestists with extensive expertise in congenital heart disease and 
pregnancy. The paper was discussed and approved by the involved bodies. 
 
Risk stratification 
The basis of meaningful pre-conception counselling and obstetric care planning is effective risk 
stratification. Several risk stratification tools are available and these provide a framework on 
which to base more individualized counselling tailored to the particular clinical scenario. Ideally, 
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prior to pregnancy, a suitably trained multi-disciplinary team should perform a comprehensive 
risk assessment, stratifying an individual’s risk and offering them appropriate counseling, 
including a discussion on the advisable mode and setting of delivery.     
 
Risk Scores 
Over the last decade a variety of risk scoring systems have been developed. The first important 
maternal cardiac study was the CARPREG (Cardiac Disease in Pregnancy) study. In the 
CARPREG scoring system, points were allocated for various risk factors, such as left ventricular 
outflow tract obstruction, diminished ventricular function, higher NYHA class and prior cardiac 
event. When studied prospectively the presence of these risk factors was associated with an 
increased risk of maternal events (1). The ZAHARA scoring system had similar predictors but 
also included the use of cardiac medication pre-pregnancy and the presence of severe 
atrioventricular valve regurgitation (2). Khairy et al identified the additional factors of smoking 
and the presence of significant right ventricular dysfunction or severe pulmonary regurgitation 
(3). More recently an alternative scoring system with a more comprehensive application - the 
Modified World Health Organisation (mWHO) risk score has been adopted (Table 3) (4). In the 
mWHO classification, patients are allocated a risk group based on their underlying cardiac 
condition. These risk groups are then associated with proposals regarding care. For example, a 
patient in risk group III, such as a patient with a mechanical valve, is said to have a “significantly 
increased risk of maternal mortality or severe morbidity”. This then triggers the 
recommendations that a woman in this risk group is cared for in a “specialist multi-disciplinary 
cardiac obstetric unit”. These risk groups have subsequently been applied to the large ESC 
registry studies (ROPAC) assessing actual maternal outcomes in patients with cardiac disease. 
This generated further useful information that can be used in risk stratification. From this registry 
a woman in mWHO Class III had a maternal mortality of 1.5% and a risk of heart failure of 19%. 
Her risk of antenatal or perinatal hospital admission due to cardiac issues was 36% (5).   
 
Other risk stratification tools   
Risk scoring systems are very informative, but are not nuanced enough to be the only basis of 
determining risk. Pre-conception investigations, including ECG, echocardiogram and exercise 
testing, are useful adjuncts. Peak heart rate and peak oxygen uptake are both known to be 
predictive of maternal cardiac events in pregnancy (6). The chronotropic response to exercise is 
also informative (7). For some patients, cardiac Magnetic Resonance (cMR) is important to 
assess systemic ventricular function, Fontan palliation or aortic dilatation/aortic coarctation.  
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More recently several groups have looked at biomarkers to further delineate risk. In women with 
heart disease, N-terminal pro-BNP can be predictive when measured at 20 weeks gestation (8). 
There are not yet enough data to be convinced that pre-conception biomarkers are equally 
useful, but tracking BNP in high-risk pregnancies is likely to be informative. Women with 
pacemakers/ICD’s in-situ should have a device interrogation within 6 months of planned 
conception to define battery longevity, arrhythmia burden and device management at the time of 
delivery (15,16). It must, however, be borne in mind that both in pregnancy and congenital heart 
disease there is unpredictability, obstetric complications and unexpected cardiac complications 
can occur, e.g multiple pregnancy or arrhythmias, and therefore the limitations of any pre-
conception risk estimation must be explained.   
 
Fetal Risk Stratification 
The major determinants of fetal outcome are prematurity and growth restriction. Recognised risk 
factors include reduced cardiac output, the presence of cyanosis and the use of medication 
such as beta-blockers (10-12). In women with severe cardiac disease, prematurity may be 
iatrogenic – with fears of maternal complications triggering early delivery. The mother should be 
counselled regarding all of these potential fetal risks.   
 
 
Counselling 
Women with CHD who wish to embark on pregnancy require pre-pregnancy counselling. Ideally 
preliminary discussions should take place during teenage years, as part of the transition 
process from paediatrics to the adult care environment.  Initial discussions should include which 
contraceptive methods are safe in the context of their underlying CHD, with emphasis on the 
importance of pre-pregnancy planning (13-17). Patients should be advised to raise pregnancy 
as a specific discussion point, as and when they themselves begin to consider motherhood.     
 
When the patient is ready to have more detailed discussions about pregnancy this should use 
all available data and information in conjunction with any lesion specific pregnancy outcomes 
reported in the medical literature. This detailed consultation should cover the following; 
 Long-term prognosis – perhaps most important in CHD lesions with significantly reduced 
life expectancy, such as atrial switch repair of transposition of the great arteries, Fontan 
circulation, pulmonary hypertension, cyanotic heart disease (18). When the data to direct 
this conversation are absent there should be an honest discussion regarding the areas 
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of uncertainty. The importance of non-cardiac risk factors should not be forgotten. This 
includes maternal age, smoking history and body mass index and other organ 
dysfunction or damage, e.g. due to syndromes. The obstetric history is another key 
component of risk as is the risk for coagulation disorders, thrombophilia and 
constellations with implications and caveats in conjunction with anaesthesia care, e.g. 
difficult airway. 
 Fertility and miscarriage rates – particularly relevant for patients with cyanotic heart 
disease and the Fontan circulation where sub-fertility is not uncommon and miscarriage 
rates are ~ 50% (19). 
 CHD recurrence risk – recurrence risk is generally estimated at 3-5%, but for some this 
risk is much higher (10-50%) (9). Where appropriate women should be given access to 
prenatal diagnosis and pre-implantation genetic diagnosis. 
 Drug therapy – drugs contra-indicated in pregnancy including Amiodarone, ACE 
inhibitors, Angiotensin receptor inhibitors, NOAC’s and Spironolactone should be 
stopped prior to conception.  Warfarin should be avoided between gestational weeks 6-
12 (20).  Advice with regards to medication that may need to be commenced in 
pregnancy tends to be lesion specific, but drugs that are commonly added include beta-
blockers, furosemide and low molecular weight heparin.  
 Estimated maternal risk and outcome – (assessment as above). Once the risk of 
pregnancy has been estimated, the discussion should turn to any known detrimental 
effect of pregnancy on a patient’s long-term health as has been reported in patients with 
a systemic right ventricle, systemic ventricular dysfunction, aortic stenosis and Marfan 
syndrome (21,22,23,24,25).  
 Expected fetal outcomes – pre-term birth, small for gestational age and growth 
restriction are particularly associated with cyanosis and impaired systemic ventricular 
function and are more common in patients with a Fontan circulation, mechanical valve or 
pulmonary hypertension (26).   
 Plans for pregnancy care – the hospital care setting, multi-disciplinary team specialists, 
frequency of visits, delivery planning and general hierarchy of antenatal care is based 
upon the maternal risk assessment and expected maternal and fetal outcomes. Any plan 
must be flexible, adaptable and responsive to the circumstances of the patient bearing in 
mind the unpredictable nature of pregnancy and CHD (27).   
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When pregnancy is contra-indicated, as in women at highest risk of death or complications 
during pregnancy (WHO IV), other options for motherhood should be discussed, including 
adoption and surrogacy. Adoption is available to anyone aged 21 years or over. There is no 
upper age limit but there is an expectation that the adoptee must have a life expectancy that 
would ensure they are able to parent a child through to independent living and that the adoptees 
health would not cause disruption or a negative impact upon the child’s education and or 
psychological well-being. There are 2 forms of surrogacy, which can be explored. In traditional 
surrogacy, the surrogate mothers egg is used making her the genetic mother, while in 
gestational surrogacy the egg is provided by the intended mother, or a donor. The egg is 
fertilised through in vitro fertilisation (IVF) and implanted into the surrogate mother. Surrogacy 
laws vary between countries. France, Germany, Italy, Spain, Portugal and Bulgaria prohibit all 
forms of surrogacy. The UK, Ireland, Denmark and Belgium, allow surrogacy provided the 
surrogate mother is not paid, other than reasonable expenses e.g. travel to antenatal visits etc.  
Commercial surrogacy (whereby a fee is paid to the surrogate mother) is allowed in some US 
states, Russia, Thailand and Ukraine.  The average cost of commercial surrogacy in the US is 
about $100,000. Advice must therefore be individualised and based on the country of citizenship 
[www.hfea.gov.uk].  In practice, surrogacy often proves difficult to achieve unless a family 
member or close friend is willing to act as a surrogate or a patient’s finances allow the option of 
seeking commercial surrogacy abroad.   
 
Prenatal diagnostics 
 
1. Timing 
Currently, the underlying cause of most congenital heart disease (CHD) is unknown, despite 
epidemiological evidence of an inherited component in at least a subset of patients. It is 
important to acknowledge though that some patients may have a transmittable genetic condition 
for which prenatal diagnostics can and should be offered and discussed (28-31). However, laws 
regarding the use of prenatal and pre-implantation testing differ substantially between countries 
and this may contribute to the fact that despite the advances in genetic techniques and their 
wider availability, counseling about genetic testing is often neglected in adult congenital heart 
disease (ACHD) clinics. Both the Canadian and American Heart associations have put forward 
recommendations for genetic testing in adults with CHD (32, 33), which are summarized in table 
1. 
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The process of genetic testing and counseling, as well as addressing the recurrence risk in all 
boys and girls with CHD, needs to take place once the mutation is identified and the counseling 
should be repeated during the transition process and thereafter at regular intervals. Patients 
with negative genetic test results in childhood may need retesting in the future as more sensitive 
genetic tests are developed. (32)  
2. Modalities for prenatal testing 
In brief, 2 options for prenatal genetic testing are available for those patients with an identified 
genetic defect (either chromosomal defects such as insertions/deletions/translocations or single 
gene defects), (i) pre-gestational diagnosis or (ii) prenatal diagnosis, chorionic villous sampling 
or amniocentesis. In the first option, pre-gestational diagnosis, embryos are made using in vitro 
fertilization (IVF) followed by an embryo biopsy performed typically on day 3 and genetic testing 
carried out on the early embryonal cell. (35,36) Non-affected embryos are used for subsequent 
transfer. The availability of both techniques is not universal and important differences in ethical 
considerations exist between countries. A survey performed in a large Dutch center in 2010 
revealed that almost 50% of patients with various established genetic disorders were unaware 
of the option of pre-gestational diagnosis, indicating the need to make information more widely 
available. (37) The second option, prenatal diagnosis, consists of screening for the familial 
mutation in fetal cells obtained at the time of chorionic villous sampling or amniocentesis, 
performed at 12 and 15 weeks of gestation respectively. (34) In case of an abnormal test result, 
the pregnancy can be terminated. In this case, the risk of having anaesthesia should be 
considered.  
Main characteristics of both techniques are explained in table 2. 
 
Generally speaking, pre-gestational diagnosis may be perceived to be an ethically more 
acceptable choice than prenatal diagnosis followed by abortion (17). However, the restricted 
availability of pre-gestational diagnosis and the need for IVF may limit the uptake of this 
approach. (37) 
 
It goes without saying prenatal options should be carefully discussed with the couple – their final 
decision should be a well-informed one and this requires a multidisciplinary approach. The 
couple should be informed about the transmission risk (50% in case of monogenetic Mendelian 
disorders) and the unpredictability of the clinical expression of some diseases such as Marfan 
syndrome. The evolving treatment opportunities for CHD should be discussed – which may be 
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very different from the situation when they were born, justifying natural pregnancy in some 
cases. Other reproductive options including remaining childless, having no genetic testing on 
any pregnancy (reproductive chance), gamete donation, surrogacy and adoption should be 
addressed. Psychological support is an absolute prerequisite and aspects related to guilt (in the 
parents) and reproach (in the offspring) need careful attention. 
 
Future developments will definitely increase the possibilities for prenatal testing. A promising 
technique is the Non Invasive Prenatal Testing method, where testing is performed on a venous 
blood sample of the pregnant woman – this method is already widely applied for aneuploidy 
testing but is rapidly evolving and testing for monogenetic diseases such as Wilson disease 
have already been set up with success. (38,39)  
 
Organization of facilities for prenatal testing requires a multidisciplinary approach and 
interdisciplinary consultations with geneticists, obstetricians and cardiologists; psychologists 
need to be available. 
 
 
Care during pregnancy 
 
There are currently no clear recommendations about the location of care management of 
pregnant women with heart disease. However, maternal and offspring risk assessment might 
help to determine the location of follow-up. The higher the risk, the more intensive and 
specialized follow-up is indicated. Ideally, the location of follow-up will have been discussed 
during pre-pregnancy counselling. (14) The mWHO classification is currently the best tool to 
estimate maternal outcome. (14,40) Follow-up of pregnant women with a mWHO class I risk can 
be organized in a local care centre, as long as the team responsible for the patient management 
has basic knowledge about potential complications related to the underlying heart disease. 
However, when complications occur, transfer to a specialised care centre with sufficient 
expertise in the patient’s heart problem, is recommended. Women with a mWHO class III or IV 
risk must be followed primarily in a highly expertized tertiary care centre. Although little data are 
available in literature (41), a multidisciplinary approach, which is in general the rule for an 
experienced centre, will probably result in a better maternal and fetal outcome. Patients with a 
maternal mWHO class II risk have a small increase in their risk of maternal mortality or 
moderate increase in morbidity and follow-up is better in an experienced tertiary care centre. 
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(13,14) In high risk-women, mWHO class III or IV, follow-up is best in a centre with tertiary level 
neonatal care management. If fetal heart disease (e.g. congenital heart disease) is discovered, 
not only fetal, but also maternal follow-up must be scheduled in a tertiary care centre. 
Frequency of follow-up is determined by the severity of the maternal risk. During pregnancy, the 
expansion in the plasma volume (50%) and of the red blood cell mass (20–30%) peaks at the 
end of the second or beginning of the third trimester. Therefore, even in patients with WHO 
class I, a single check-up around 20-24 weeks is advised. Indeed, the results of the risk 
assessment might change during pregnancy. If complications occur, more frequent follow-up is 
needed. For patients with a mWHO class II risk assessment, a check-up in each trimester of the 
pregnancy is recommended. For the high-risk patients (mWHO class III – IV) a more frequent 
assessment is necessary, a minimum of a monthly review is mandatory and this is often 
increased to weekly. (42) 
The nature and extent of investigations during follow-up depends on the underlying heart 
disease. In addition to asking focussed questions and performing a physical examination, a 
resting electrocardiogram and a transthoracic echocardiography should be carried out at 
intervals. (43) Holter monitoring is indicated in women with palpitations and mandatory in the 
presence of a previously documented arrhythmia. Ionizing radiation should be avoided if 
possible, but can be considered if it is critical to management and the information cannot be 
otherwise obtained. (44) Cardiac MR might be indicated in complex heart disease and aortic 
pathology (43) and is considered to be safe from 12 weeks of gestation; however, gadolinium 
contrast should be avoided, unless critical. (45, 46) In diseases involving a high likelihood for 
vascular malformations located in the lumbar spine, it could be advisable to assess the lumbar 
spine in view of the need for central neuraxial analgesia / anaesthesia (via MRI). Routine 
laboratory testing specifically for the underlying heart defect is not indicated, however, 
myocardial ischemia or heart failure might be ruled out by elevated serum troponin I or BNP 
levels, respectively. In patients with associated haematological disorders, or in patients treated 
with oral anticoagulants, regular blood sampling is indicated. (47,48) Exercise testing can be 
recommended for further patient management during pregnancy, but is not part of the routine 
follow-up. 
Hospital admission during pregnancy is not uncommon and indicated when maternal, obstetric, 
or fetal complications occur. Indeed hospital admission with bedrest is advised to reduce the 
hemodynamic load in a woman with heart failure. In the large prospective ROPAC registry, 
which included pregnant women with cardiac disease, 26% of patients were admitted during 
pregnancy in the majority of cases, for cardiac reasons. (14) In pregnant women with a 
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mechanical valve, the incidence of hospital admission reached 36.7%. (49) Heart failure was the 
most common cause of hospitalization, while thrombotic and haemorrhagic complications 
occurred most frequently in patients with a mechanical valve. (14,49) Admission for myocardial 
ischaemia, arrhythmia and endocarditis are less common. There are no clear recommendations 
regarding when hospital admission is necessary for cardiac reasons, but it is obvious in those 
who need close monitoring, intravenous drug therapy or mechanical support.  
Pregnant patients with heart failure are advised to reduce their physical activity and to limit their 
fluid intake. More frequent clinical follow-up and a low threshold for hospital admission are 
indicated. In the case of a marked deterioration, decisions for mechanical support, device 
therapy and urgent transplantation may need to be taken, all of which carry a substantially 
higher risk of an adverse fetal outcome. 
Indeed, several heart conditions have a greater risk of arrhythmia, not only during, but also 
outside pregnancy. When supraventricular arrhythmia occurs and triggers hemodynamic 
instability, direct current (DC) cardioversion should be applied. (50). Although the DC current 
exposure to the fetus is minimal, fetal monitoring during the procedure is recommended. Both 
cardiac or non-cardiac surgical interventions may occasionally be necessary during pregnancy. 
It is better to postpone elective surgery until after delivery, semi-urgent or urgent interventions 
have to take place during pregnancy. Non-cardiac surgery in pregnant women with a WHO 
class I risk can probably be safely performed in a secondary centre. However, when there is a 
potential risk for fetal distress during surgery requiring urgent delivery, then the patient is better 
transferred to a tertiary centre with experienced interdisciplinary (obstetric, neonatal, 
anaesthesia) staff. Non-cardiac surgery, in pregnant women with WHO class II-IV risk, is 
preferable performed in a tertiary centre with sufficient expertise in the relevant cardiac 
condition and in neonatal care. Surgery in the first - and in the third trimester of the pregnancy 
carries a higher risk of fetal malformations and pre-term delivery, respectively. (14) Therefore, 
surgery is best performed between the 13th and 28th week.  
Cardiac surgery requiring cardiopulmonary bypass after 26 weeks has a fetal survival rate of 
80%, but with 20% having serious neurological impairment. For this reason, Caesarean delivery 
may be considered first if gestational age is more than 26 weeks. However, before surgery, 
antenatal corticosteroids, to mature the fetal lungs, should be administered. If cardiopulmonary 
bypass is needed in a pregnant patient, then normothermic perfusion is advised and 
hypocapnia, responsible for utero-placental vasoconstriction, and fetal hypoxia have to be 
avoided. The duration of the cardiopulmonary bypass should be minimized. (51) 
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Delivery 
 
All women with heart disease should be delivered in an obstetric-led setting, most commonly in 
the labour ward, but occasionally in a cardiac theatre if close cardiac monitoring, with 
transoesophageal echo for example, is required or the need for acute cardiac intervention, 
including extracorporeal circulation, is anticipated. An experienced multidisciplinary team should 
be available to provide care. Lower risk cases, mWHO class I, can be managed in secondary 
centres, but high-risk cases, mWHO class II-IV, should be cared for in a tertiary centre with 
access to cardiac surgery. The plan of care during delivery should be determined in the 
antenatal period, preferably around 25 weeks of pregnancy.  
Mode of delivery: The data from ROPAC show that vaginal delivery is associated with a better 
birthweight (52). Vaginal delivery is associated with smaller blood volume changes and is less 
often complicated by haemorrhage, thrombosis and infection. However, a Caesarean section 
(CS) should be planned for the usual obstetric indications and in cases with an aortic root 
diameter of >4.5cm, acute heart failure or severe pulmonary hypertension. Similarly, an 
emergency CS should be performed for the usual obstetric indications and if a case presents in 
preterm labour while taking oral anticoagulants (14). In this situation, the CS should be 
performed under general anaesthesia with Fresh Frozen Plasma cover and with prothrombin 
complex concentrate available. Haemostasis must be meticulous to avoid haematoma formation 
and the risk of infection. In order to avoid emergency CS and to ensure optimal logistics and 
risk-minimization, planned CS seems also be a viable option in situations where CS per se may 
not have an absolute indication. This is especially true in view of the anticoagulation 
management and the appropriate termination to prevent complications in conjunction with 
central neuraxial anaesthesia. 
Induction of labour should be performed for the usual obstetric indications. At the dose used for 
induction of labour, both PGE2 and oxytocin are safe with no reported adverse cardiovascular 
effects. Induction may be indicated when a patient is taking anticoagulants to better time the 
cessation of therapy, allowing epidural analgesia to be used for vaginal delivery and to avoid 
intra or post partum haemorrhage.  
Labour: Women should be transferred to the delivery room early in labour to facilitate siting of 
the epidural and initiation of maternal and fetal monitoring, including blood pressure, heart 
rhythm and saturation monitoring. Haemodynamic stability is essential and facilitated by early 
epidural insertion and careful fluid balance management avoiding dehydration and fluid 
14 
 
overload. The initial epidural doses should be low and gradually increased to achieve effective 
pain relief. Continuous electronic fetal monitoring should be used throughout labour. Infective 
endocarditis in pregnancy is rare and at present antibiotic prophylaxis is not routinely 
recommended during CS or vaginal delivery although this is disputed. (53) When the cervix is 
fully dilated, 2 hours of passive descent should be allowed. The duration of the active phase of 
the second stage should be limited in some cases; however, in all cases, if there is poor 
maternal effort or no progress during the second stage, then assisted delivery should be 
performed early using either ventouse or forceps. 
Current recommendations are to manage the third stage with a low dose oxytocin infusion (14) 
because of concern about hypotension, tachycardia and myocardial ischaemia, due to 
vasodilatation of subcutaneous vessels, vasoconstriction of the coronary arteries and a 
chronotropic effect (54-56). However if this proves inadequate, prompt management of uterine 
atony with physical methods, bimanual compression, intrauterine balloon or uterine brace 
sutures, and pharmacological agents including slow administration of bolus oxytocin (5iu) and 
an oxytocin infusion (40iu over 4 hours) is required. Misoprostol is effective at a dose of 400μg, 
but may cause hypotension and hyperthermia (57). Care should be taken in the use of 
prostaglandin F2α analogues, which can cause severe vasoconstriction. Ergometrine, which can 
cause hypertension and coronary artery spasm, should be avoided where possible, but can be 
considered if uterine atony is hard to control in those who do not have aortopathy or pre-
eclampsia. Sulprostone for treatment of postpartum haemorrhage should not be delayed, but 
rather carefully titrated with appropriate monitoring. 
In the early post-natal period up to 48 hours, high-risk cases should be kept under close 
observation, particularly those with heart failure or aortopathy; imaging of the aortic root should 
be performed as indicated. Some patients, especially those with pulmonary hypertension may 
require inpatient monitoring for up to 1 or 2 weeks. The process of uterine contraction/involution 
produces an auto-transfusion of about 500mls of blood into the circulation, which may 
precipitate cardiac failure. However, most hemodynamic changes are reversed within two 
weeks with further normalization towards preconception values after 2 months. Some 
pregnancy changes may take longer to resolve or indeed never completely resolve.  
Breast-feeding is rarely a problem and should be encouraged except in those with severe heart 
failure, where the extra energy expenditure may be detrimental. Some cardiac medications have 
been suggested to cause neonatal problems, amiodarone should be avoided if possible. ACE 
inhibitors are linked to neonatal hypotension and infant blood pressure should be monitored 
carefully, and beta blockers may cause bradycardia, hypoglycaemia and failure to thrive, but the 
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amount in breast milk is generally too little to affect infants. Mastitis should be treated 
aggressively with intravenous antibiotics. 
 
Specific issues for low resource setting 
The maternal mortality in low-to-middle income countries (LMIC) is 14 times higher than in high-
income countries (HIC) (58) and recognising this, the reduction of maternal mortality was the 
first target for the new Sustainable Development Goal (SDG) for health (59). While direct 
causes of maternal death such as obstetric haemorrhage, sepsis and hypertensive disease 
remain the largest contributors, heart disease in pregnancy is a common problem in all 
countries (60-62) with a disease profile that includes poverty-related conditions such as 
rheumatic heart disease, peripartum and other cardiomyopathies as well as un-operated 
congenital heart disease. Risk-factors contributing to the morbidity and mortality of pre-existing 
heart disease in pregnant women such as hypertension, obesity and diabetes are increasingly 
important, occurring in high numbers in some countries, urban settings and specific sub-
populations in Asia, Latin-America and sub-Saharan Africa.   
To improve pregnancy outcomes through the identification and referral of patients requiring 
specialist care, the basic elements of clinical assessment need to be in place reliably and 
consistently. Efforts to develop sustainable specialist services should be built on a health 
systems strengthening approach and supported by the appropriate resourcing plans, in 
particular the Global Financing Facility (63). As we move to the era of the SDGs the needs of 
‘very sick obstetric patients’ are starting to be more clearly articulated (64).  
Recommendations for the organisation of care for pregnancy in patients with heart disease in 
LMICs are presented in table 3 (65). Following delivery, appropriate postnatal family planning 
needs to be offered using an effective method and, where patients are being managed with 
anticoagulation, taking into account the adverse impact of some hormonal-based methods. 
Finally, support from cognate clinical services especially anaesthesiology during clinical care 
especially around the time of delivery is essential. Active strategies for suspected and 
previously known cardiac disease in pregnancy are expected to avoid a substantial portion of 
maternal morbidity and mortality. 
 
Conclusion 
This paper complements the existing guidelines, giving practical advice about setting up a clinic 
for pregnant women with heart disease in both high and low income countries. It focuses on the 
16 
 
importance of the pre-conception appointment, when key decisions will be made about 
operative corrections or changes in therapy to optimize maternal health prior to conception, 
describes the essential components for the care  during and after pregnancy in cardiac patients, 
while establishing the principle that the higher the risk then the greater the level and intensity of 
follow up is needed.  
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Table 1. Recommendations for genetic testing and counseling in ACHD patients 
1. A detailed family history for CHD and other birth defects spanning at least 3 
generations should be taken to identify familial inheritance. (AHA Class I; Level of 
Evidence C).  
2. As some CHD defects such as BAV or ASD may go unnoticed into adulthood, 
additional clinical evaluation in family members with echocardiography is reasonable 
(AHA Class IIa; Level of Evidence C). 
3. Detailed history and physical examination should be performed to detect 
dysmorphic features, extracardiac malformations, and other organ system 
involvement (AHA Class I; Level of Evidence C). 
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Table 2: Main characteristics of Prenatal chorionic villous sampling or amniocentesis (PND) and 
Pre-gestational diagnostics (PGD) 
 
 
PND: 
  No artificial pregnancy 
  No need for hormonal stimulation 
Risk of fetal loss  
  Emotional burden of terminating pregnancy 
 
PGD: 
  No emotional and moral issues related to terminating pregnancy 
  Technically complex procedure – hormonal stimulation  
 No anaesthesia needed 
  Long waiting lists  
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Table 3. Recommendations for the organisation of care (66)) 
 
Context Recommendation 
Routine ANC All pregnant women should be screened at antenatal booking for 
underlying medical or surgical conditions 
Known  
disease 
Women with known or recently detected cardiovascular disease should 
undergo risk assessment based on a published algorithm (Sliwa et al. 
2014) 
Unstable 
clinical state 
Women presenting with difficulty in breathing, systolic blood pressure of 
<100mmHg, heart rate > 120 beats per minute or appearing cyanotic need 
to be transferred by ambulance to a tertiary centre within 12 hours; those 
presenting with signs of fluid overload should receive a bolus of furosemide 
40mg IV and oxygen per face mask prior to transfer 
Pregnancy 
and Postnatal 
surveillance 
Clinicians should have a low threshold for investigating pregnant or recently 
delivered women (up to 6 months post-partum), especially those with 
cardiovascular risk factors (hypertension, diabetes), suspected rheumatic 
heart disease or with symptoms such as shortness of breath, a respiratory 
rate exceeding 20 breaths/min. or chest pain.  Appropriate investigations 
include ECG, chest x-ray, echocardiogram and CT pulmonary angiography 
will aid decision making about the mode and timing of delivery and 
postpartum management. 
Extended 
follow up for 
High Risk 
patients 
Certain patients with high-risk cardiovascular disease might need careful 
monitoring for up to 1 year post-partum owing to a high risk of developing 
heart failure, serious arrhythmia and embolic events. 
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Table 4 Organisation of care for women with congenital heart disease concerning 
pregnancy 
 
 mWHO1 mWHO2  mWHO2-3 mWHO3 mWHO4 
Diagnosis *Uncomplicated 
small or mild 
-PS, -PDA, -MVP 
*Successfully 
repaired simple 
lesions (ASD, VSD, 
PDA,anomalous 
PVD) 
If otherwise well 
and 
uncomplicated: 
*Unoperated 
ASD, VSD 
*repaired ToF 
*most 
arrhythmias 
Depending on 
individual: 
*mild LV 
impairment 
*HCM 
*native or tissue 
valve disease not 
considered WHO 1 
or 4 
*Marfan without 
aortic dilatation 
*repaired 
coarctation 
*mechanical valve 
*systemic RV 
*Fontan 
*unrepaired 
cyanotic heart 
disease 
*other complex 
heart disease 
* mild aortic 
dilatation (Marfan 
40-45mm; BAV 45-
50mm) 
*Pulmonary arterial 
hypertension 
*severe systemic 
ventricular 
dysfunction (EF <30%) 
*previous PPCM with 
any residual LV 
impairment 
*severe MS 
*severe symptomatic 
AS 
Severe aortic dilatation 
(Marfan >45mm, BAV 
>50mm) 
Risk  No detectable 
increased risk of 
maternal 
mortality and 
no/mild 
increased risk in 
morbidity 
Small increased 
risk of maternal 
mortality ot 
moderate 
increase in 
morbidity 
Intermediate 
increased risk of 
maternal mortality 
or moderate to 
severe increase in 
morbidity 
Significantly 
increased risk of 
maternal mortality 
or severe 
morbidity 
Extremely high risk of 
maternal mortality or 
severe morbidity 
Counselling yes yes yes Expert counselling 
required 
Pregnancy 
contraindicated. 
If pregnancy occurs 
termination should be 
discussed 
Care during 
pregnancy 
Local hospital Local hospital Referral hospital Expert center for 
Pregnancy and 
Cardiac disease 
Expert center for 
Pregnancy and Cardiac 
disease 
Location of 
delivery 
Local hospital Local hospital Referral hospital Expert center for 
Pregnancy and 
Cardiac disease 
Expert center for 
Pregnancy and Cardiac 
disease 
 
 
